VC: San Diego biotechs raise $143M



San Diego biotechs raise $143M.

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Verus Pharmaceuticals
San Diego

$78M/$20M loan
first round

Domain Associates, Prospect Venture Partners

Verus plans to in-license pediatric drugs and move quickly to Phase III.

Somaxon Pharmaceuticals
San Diego

$65M
third round

MPM Capital Partners

Somaxon has an insomnia drug -- Silenor -- in Phase III.

Osiris Therapeutics
Baltimore

$50M
undisclosed

Friedli Corporate

Osiris is in a race to become the first biotech to commercialize stem cell products.

Ziopharm
Charlestown, MA

$18.1M
first round

Paramount BioCapital

Ziopharm is looking to in-license cancer products.

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.